{"target":{"股票代码":"600276.SH","股票名称":"恒瑞医药","当前价格":48.22,"总市值":307595489652.28,"流通市值":307595489652.28,"总股本":6379002274.0,"流通股本":6379002274.0,"分析时间":"2025-03-27 00:00:00","PE统计":{"扣非PE(TTM)":56.99,"扣非PE(TTM)备注":"","动态PE":49.939,"动态PE备注":"","当前PEG":1.525,"PEG备注":"比较 2023-09-30 vs 2024-09-30；利润表字段 DEDUCT_PARENT_NETPROFIT_YOY；使用扣非PE(TTM)","净利润增长率":0.374},"PB统计":{"当前PB":6.939},"PS统计":{"当前PS":11.833},"历史PE数据":[{"报告期":"2023-03-31","TTM净利润(亿元)":34.497,"TTM每股收益(元)":0.541,"股价(元)":42.31,"PE":78.237,"PB":6.94},{"报告期":"2023-06-30","TTM净利润(亿元)":36.443,"TTM每股收益(元)":0.571,"股价(元)":47.49,"PE":83.128,"PB":7.796},{"报告期":"2023-09-30","TTM净利润(亿元)":37.187,"TTM每股收益(元)":0.583,"股价(元)":44.56,"PE":76.439,"PB":7.171},{"报告期":"2023-12-31","TTM净利润(亿元)":41.413,"TTM每股收益(元)":0.649,"股价(元)":44.85,"PE":69.085,"PB":7.07},{"报告期":"2024-03-31","TTM净利润(亿元)":43.616,"TTM每股收益(元)":0.684,"股价(元)":45.58,"PE":66.662,"PB":6.944},{"报告期":"2024-06-30","TTM净利润(亿元)":53.88,"TTM每股收益(元)":0.845,"股价(元)":38.13,"PE":45.143,"PB":5.707},{"报告期":"2024-09-30","TTM净利润(亿元)":53.974,"TTM每股收益(元)":0.846,"股价(元)":52.11,"PE":61.587,"PB":7.595}],"历史PEG数据":[{"报告期":"2023-03-31","PE":78.237,"净利润同比增长率(%)":3.398,"PEG":23.022},{"报告期":"2023-06-30","PE":83.128,"净利润同比增长率(%)":11.681,"PEG":7.117},{"报告期":"2023-09-30","PE":76.439,"净利润同比增长率(%)":10.128,"PEG":7.547},{"报告期":"2023-12-31","PE":69.085,"净利润同比增长率(%)":21.458,"PEG":3.22},{"报告期":"2024-03-31","PE":66.662,"净利润同比增长率(%)":18.058,"PEG":3.691},{"报告期":"2024-06-30","PE":45.143,"净利润同比增长率(%)":55.577,"PEG":0.812},{"报告期":"2024-09-30","PE":61.587,"净利润同比增长率(%)":37.382,"PEG":1.647}],"价格极值回顾":[{"类别":"三年最高价","价格日期":"2024-10-08","价格(元)":55.81,"参考财报日期":"2024-09-30","TTM净利润(亿元)":53.974,"扣非PE":65.96,"扣非净利润同比增长率(%)":37.382,"PEG":1.764},{"类别":"一年最高价","价格日期":"2024-10-08","价格(元)":55.81,"参考财报日期":"2024-09-30","TTM净利润(亿元)":53.974,"扣非PE":65.96,"扣非净利润同比增长率(%)":37.382,"PEG":1.764},{"类别":"三个月最高价","价格日期":"2025-03-27","价格(元)":48.22,"参考财报日期":"2024-09-30","TTM净利润(亿元)":53.974,"扣非PE":56.99,"扣非净利润同比增长率(%)":37.382,"PEG":1.525},{"类别":"三年最低价","价格日期":"2022-04-26","价格(元)":27.3,"参考财报日期":"2022-03-31","TTM净利润(亿元)":39.094,"扣非PE":44.545,"扣非净利润同比增长率(%)":-19.796,"PEG":null}]},"similar":[{"股票代码":"688235.SH","股票名称":"百济神州","当前价格":231.66,"总市值":322903392308.64,"流通市值":322903392308.64,"总股本":1393867704.0,"流通股本":1393867704.0,"分析时间":"2025-03-27 00:00:00","PE统计":{"扣非PE(TTM)":-46.873,"扣非PE(TTM)备注":"","动态PE":-65.69,"动态PE备注":"","当前PEG":null,"PEG备注":"比较 2023-09-30 vs 2024-09-30；利润表字段 DEDUCT_PARENT_NETPROFIT_YOY；PEG因PE或增速为非正值而置为None","净利润增长率":0.412},"PB统计":{"当前PB":13.358},"PS统计":{"当前PS":13.634},"历史PE数据":[{"报告期":"2023-03-31","TTM净利润(亿元)":-135.772,"TTM每股收益(元)":-9.741,"股价(元)":130.81,"PE":-13.429,"PB":6.376},{"报告期":"2023-06-30","TTM净利润(亿元)":-126.491,"TTM每股收益(元)":-9.075,"股价(元)":109.11,"PE":-12.023,"PB":5.517},{"报告期":"2023-09-30","TTM净利润(亿元)":-100.593,"TTM每股收益(元)":-7.217,"股价(元)":141.25,"PE":-19.572,"PB":7.208},{"报告期":"2023-12-31","TTM净利润(亿元)":-96.819,"TTM每股收益(元)":-6.946,"股价(元)":139.04,"PE":-20.017,"PB":7.72},{"报告期":"2024-03-31","TTM净利润(亿元)":-91.147,"TTM每股收益(元)":-6.539,"股价(元)":132.2,"PE":-20.217,"PB":7.64},{"报告期":"2024-06-30","TTM净利润(亿元)":-73.049,"TTM每股收益(元)":-5.241,"股价(元)":115.84,"PE":-22.104,"PB":6.651},{"报告期":"2024-09-30","TTM净利润(亿元)":-68.888,"TTM每股收益(元)":-4.942,"股价(元)":180.46,"PE":-36.514,"PB":10.406}],"历史PEG数据":[{"报告期":"2023-03-31","PE":-13.429,"净利润同比增长率(%)":8.64,"PEG":null},{"报告期":"2023-06-30","PE":-12.023,"净利润同比增长率(%)":17.602,"PEG":null},{"报告期":"2023-09-30","PE":-19.572,"净利润同比增长率(%)":35.693,"PEG":null},{"报告期":"2023-12-31","PE":-20.017,"净利润同比增长率(%)":29.965,"PEG":null},{"报告期":"2024-03-31","PE":-20.217,"净利润同比增长率(%)":21.701,"PEG":null},{"报告期":"2024-06-30","PE":-22.104,"净利润同比增长率(%)":43.204,"PEG":null},{"报告期":"2024-09-30","PE":-36.514,"净利润同比增长率(%)":41.176,"PEG":null}],"价格极值回顾":[{"类别":"三年最高价","价格日期":"2025-02-28","价格(元)":238.41,"参考财报日期":"2024-09-30","TTM净利润(亿元)":-68.888,"扣非PE":-48.239,"扣非净利润同比增长率(%)":41.176,"PEG":-1.172},{"类别":"一年最高价","价格日期":"2025-02-28","价格(元)":238.41,"参考财报日期":"2024-09-30","TTM净利润(亿元)":-68.888,"扣非PE":-48.239,"扣非净利润同比增长率(%)":41.176,"PEG":-1.172},{"类别":"三个月最高价","价格日期":"2025-02-28","价格(元)":238.41,"参考财报日期":"2024-09-30","TTM净利润(亿元)":-68.888,"扣非PE":-48.239,"扣非净利润同比增长率(%)":41.176,"PEG":-1.172},{"类别":"三年最低价","价格日期":"2022-05-12","价格(元)":83.46,"参考财报日期":"2022-03-31","TTM净利润(亿元)":-103.226,"扣非PE":-11.27,"扣非净利润同比增长率(%)":-965.944,"PEG":null}]},{"股票代码":"600196.SH","股票名称":"复星医药","当前价格":24.7,"总市值":65981763685.5,"流通市值":65959604327.5,"总股本":2671326465.0,"流通股本":2670429325.0,"分析时间":"2025-03-27 00:00:00","PE统计":{"扣非PE(TTM)":28.51,"扣非PE(TTM)备注":"","动态PE":23.821,"动态PE备注":"","当前PEG":1.887,"PEG备注":"比较 2023-12-31 vs 2024-12-31；利润表字段 DEDUCT_PARENT_NETPROFIT_YOY；使用扣非PE(TTM)","净利润增长率":0.151},"PB统计":{"当前PB":1.101},"PS统计":{"当前PS":1.607},"历史PE数据":[{"报告期":"2023-03-31","TTM净利润(亿元)":39.911,"TTM每股收益(元)":1.494,"股价(元)":31.21,"PE":20.889,"PB":1.837},{"报告期":"2023-06-30","TTM净利润(亿元)":33.835,"TTM每股收益(元)":1.267,"股价(元)":29.77,"PE":23.504,"PB":1.749},{"报告期":"2023-09-30","TTM净利润(亿元)":24.876,"TTM每股收益(元)":0.931,"股价(元)":27.95,"PE":30.014,"PB":1.626},{"报告期":"2023-12-31","TTM净利润(亿元)":20.106,"TTM每股收益(元)":0.753,"股价(元)":24.46,"PE":32.497,"PB":1.43},{"报告期":"2024-03-31","TTM净利润(亿元)":16.999,"TTM每股收益(元)":0.636,"股价(元)":22.54,"PE":35.421,"PB":1.299},{"报告期":"2024-06-30","TTM净利润(亿元)":18.921,"TTM每股收益(元)":0.708,"股价(元)":21.64,"PE":30.552,"PB":1.231},{"报告期":"2024-09-30","TTM净利润(亿元)":23.73,"TTM每股收益(元)":0.888,"股价(元)":27.35,"PE":30.789,"PB":1.545},{"报告期":"2024-12-31","TTM净利润(亿元)":23.144,"TTM每股收益(元)":0.866,"股价(元)":24.56,"PE":28.348,"PB":1.388}],"历史PEG数据":[{"报告期":"2023-03-31","PE":20.889,"净利润同比增长率(%)":14.779,"PEG":1.413},{"报告期":"2023-06-30","PE":23.504,"净利润同比增长率(%)":-26.276,"PEG":null},{"报告期":"2023-09-30","PE":30.014,"净利润同比增长率(%)":-48.448,"PEG":null},{"报告期":"2023-12-31","PE":32.497,"净利润同比增长率(%)":-48.082,"PEG":null},{"报告期":"2024-03-31","PE":35.421,"净利润同比增长率(%)":-33.806,"PEG":null},{"报告期":"2024-06-30","PE":30.552,"净利润同比增长率(%)":-8.637,"PEG":null},{"报告期":"2024-09-30","PE":30.789,"净利润同比增长率(%)":24.583,"PEG":1.252},{"报告期":"2024-12-31","PE":28.348,"净利润同比增长率(%)":15.105,"PEG":1.877}],"价格极值回顾":[{"类别":"三年最高价","价格日期":"2022-03-30","价格(元)":52.47,"参考财报日期":"2021-12-31","TTM净利润(亿元)":32.773,"扣非PE":42.768,"扣非净利润同比增长率(%)":20.599,"PEG":2.076},{"类别":"一年最高价","价格日期":"2024-10-08","价格(元)":28.86,"参考财报日期":"2024-09-30","TTM净利润(亿元)":23.73,"扣非PE":32.488,"扣非净利润同比增长率(%)":24.583,"PEG":1.322},{"类别":"三个月最高价","价格日期":"2025-02-17","价格(元)":25.83,"参考财报日期":"2024-12-31","TTM净利润(亿元)":23.144,"扣非PE":29.814,"扣非净利润同比增长率(%)":15.105,"PEG":1.974},{"类别":"三年最低价","价格日期":"2024-02-05","价格(元)":20.71,"参考财报日期":"2023-12-31","TTM净利润(亿元)":20.106,"扣非PE":27.515,"扣非净利润同比增长率(%)":-48.082,"PEG":null}]}],"comparison_table":[{"股票代码":"600276.SH","股票名称":"恒瑞医药","角色":"目标股票","当前价格":48.22,"当前扣非PE(TTM)":56.99,"动态PE":49.939,"当前PEG":1.525,"净利润增长率":"37.382%","当前PB":6.939,"当前PS":11.833,"备注":"比较 2023-09-30 vs 2024-09-30；利润表字段 DEDUCT_PARENT_NETPROFIT_YOY；使用扣非PE(TTM)"},{"股票代码":"688235.SH","股票名称":"百济神州","角色":"相似股票","当前价格":231.66,"当前扣非PE(TTM)":-46.873,"动态PE":-65.69,"当前PEG":NaN,"净利润增长率":"41.176%","当前PB":13.358,"当前PS":13.634,"备注":"百济神州是中国创新药领域的领军企业之一，尤其在抗肿瘤药物研发方面与恒瑞医药构成了直接且激烈的竞争关系。两家公司都在PD-1/PD-L1抑制剂等热门靶点上拥有重磅产品，并在积极拓展海外市场，争夺全球市场份额，因此在技术路径、市场策略和未来发展方向上高度相似。"},{"股票代码":"600196.SH","股票名称":"复星医药","角色":"相似股票","当前价格":24.7,"当前扣非PE(TTM)":28.51,"动态PE":23.821,"当前PEG":1.887,"净利润增长率":"15.105%","当前PB":1.101,"当前PS":1.607,"备注":"复星医药业务覆盖药品制造与研发、医疗器械、医学诊断和医疗服务等多个领域，其药品业务同样以抗肿瘤药物为核心之一，与恒瑞医药存在直接竞争。复星医药通过自主研发、合作开发和许可引进等多种方式布局创新药管线，在产品结构和市场竞争层面与恒瑞医药有很高的重叠度。"}]}